All AbMole products are for research use only, cannot be used for human consumption.
(-)-Epigallocatechin Gallate (EGCG) inhibits activation EGFR, HER2 and HER3 in the SW837 human colon cancer cell line. (-)-Epigallocatechin Gallate (10 μM) also inhibits cell growth, suppresses activation of EGFR, HER2, and HER3, and causes decrease in the levels of COX-2 and Bcl-xL proteins, and apoptosis after treatment for 96 h. In vivo, (-)-Epigallocatechin Gallate (5, 10, and 20 mg/kg, p.o.) inhibits the growth of orthotopic colorectal cancer cells in mice.
Sci Rep. 2025 Nov 28;15(1):42738.
Epigallocatechin-3-gallate ameliorates lipopolysaccharide-induced inflammation via the 67LR/JAK2/STAT3 signaling pathway
(-)-Epigallocatechin gallate purchased from AbMole
| Cell Experiment | |
|---|---|
| Cell lines | 786-O cells and ACHN cells (human renal cell carcinoma cell lines) |
| Preparation method | Cell lines 786-O and ACHN were plated into 96-well plates at a density of 2×10⁴ cells/well in RPMI 1640 culture medium and incubated at 37°C for 24 h. Subsequent to treatment with EGCG at various concentrations (0, 5, 10, 20, 40 and 60 µg/ml) for 12, 24 and 48 h, the cells were incubated with 20 µl MTT (5 mg/ml) at 37°C for 4 h. Following this, the medium was removed and 150 µl dimethyl sulfoxide was added to each well for 10 min at room temperature to solubilize the crystals. Finally, cell proliferation was determined by absorbance measurements at 490 nm on a Model 680 microplate reader. Cell viability was expressed as a percentage of the absorbance obtained for the control group. A minimum of three independent experiments were performed. |
| Concentrations | 0, 5, 10, 20, 40 and 60 µg/ml |
| Incubation time | 12, 24 and 48 h |
| Animal Experiment | |
|---|---|
| Animal models | Ts65Dn mice and euploid mice on ~50% C57BL/6J and ~50% C3H/HeJ background, male, 6-week-old |
| Formulation | EGCG dissolved in phosphate buffered saline (PBS) at a concentration of 15 mg/mL, prepared fresh daily |
| Dosages | 200 mg/kg/day |
| Administration | Oral gavage (13.34 mL/kg body weight) once daily for two days (acute treatment) or from postnatal day 42 to postnatal day 68 (chronic treatment) |
| Molecular Weight | 458.37 |
| Formula | C22H18O11 |
| CAS Number | 989-51-5 |
| Solubility (25°C) | DMSO 20 mg/mL Water 15 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related EGFR/HER2 Products |
|---|
| AEE788
AEE788 (NVP-AEE788) is a novel multitargeted HER 1/2 and VEGFR 1/2 receptor family tyrosine kinases inhibitor with IC50 of 2, 6, 77, 59 nM for EGFR, ErbB2, KDR, and Flt-1. |
| Sapitinib (AZD8931)
AZD8931 (Sapitinib) is an equipotent, reversible inhibitor of Signaling by EGFR, ERBB2 (HER2), and ERBB3 with IC50 of 4, 3, 4 nM respectively. |
| Afatinib
Afatinib (BIBW 2992) is a novel irreversible dual EGFR and HER2 tyrosine kinase inhibitor. |
| CP-724714
CP-724714 is a potent and selective orally active HER-2 tyrosine kinase inhibitor, IC50 = 3 nM. |
| Icotinib
Icotinib (BPI-2009H) is a potent and novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with an IC50 of 5 nM. Iconitib inhibits the proliferation of A431 and BGC-823 A549, H460 and KB cell lines with IC50s of 1, 4.06, 12.16, 16.08, 40.71 μM. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
